Last reviewed · How we verify
Tolterodine Tartrate ER
Tolterodine tartrate is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency.
Tolterodine tartrate is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.
At a glance
| Generic name | Tolterodine Tartrate ER |
|---|---|
| Also known as | Detrol LA, Detrol (TM), Detrusitol SR, Mariosea XL, Detrol LA™ |
| Sponsor | University of California, San Francisco |
| Drug class | Muscarinic receptor antagonist |
| Target | M2 and M3 muscarinic receptors |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | FDA-approved |
Mechanism of action
Tolterodine selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking these receptors, it prevents acetylcholine-mediated bladder contractions, thereby increasing bladder capacity and reducing the frequency of micturition. The extended-release formulation provides sustained therapeutic effect over 24 hours.
Approved indications
- Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency
Common side effects
- Dry mouth
- Headache
- Constipation
- Dizziness
- Blurred vision
Key clinical trials
- TReating Incontinence for Underlying Mental and Physical Health (PHASE4)
- The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial (PHASE3)
- Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder (PHASE3)
- A Study of YM178 in Subjects With Symptoms of Overactive Bladder (PHASE3)
- Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
- Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
- Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg (PHASE1)
- An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB). (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tolterodine Tartrate ER CI brief — competitive landscape report
- Tolterodine Tartrate ER updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI